ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
Resolved · corporate · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-25. Check what remains unresolved below before relying on it.
What does this change in the investment case for ADARx Pharmaceuticals?
Successful upsized primary ECM execution injects 446.3M USD into clinical RNA therapeutics, setting valuation benchmarks for late-stage biotech issuance.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million shares at $17.00 per share. |
| What else was confirmed? | Reported factGross proceeds generated total approximately $446.3 million. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for ADRX yet — this is the next research task. |
| What would change the assessment? | UnknownADRX opening trade price — First trades and indicative order book balance on Nasdaq around 9:30-10:00 AM ET |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million shares at $17.00 per share.
- · Gross proceeds generated total approximately $446.3 million.
- · The company begins trading on the Nasdaq Global Market on September 25, 2026, under ticker symbol 'ADRX'.
Public research record
Research framework · page evidenceCompleted event assessment
new public market equity listing and liquidity intake
| Type | Claim | Scope |
|---|---|---|
| Assumption | ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million shares at $17.00 per share. | 2026-09-25 |
| Interpretation | new public market equity listing and liquidity intake | ADRX |
Countercase, invalidators, and sources
ADRX trades with a solid first-day premium above $17, reinforcing primary market access for peer clinical stage biopharma.
- · ADRX opening trade price — First trades and indicative order book balance on Nasdaq around 9:30-10:00 AM ET
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering · 2026-09-24
What remains unresolved
- Base path
- ADRX stabilizes around the $17 offer price with orderly institutional allocations.
- Adverse path
- Broad equity rate pressures cause ADRX to break issue price on market open.
- Supportive path
- ADRX trades with a solid first-day premium above $17, reinforcing primary market access for peer clinical stage biopharma.
- · ADRX opening trade price — First trades and indicative order book balance on Nasdaq around 9:30-10:00 AM ETtoday
Evidence
- ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering2026-09-24
“ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing siRNA therapeutics, priced its IPO at $17 per share for 26.25 million shares, generating approximately $446.3 million in gross proceeds. The company will begin trading on Nasdaq under ticker 'ADRX' on September 25, 2026.”
Supports: ADARx priced upsized IPO of 26.25 million shares at $17 per share to raise $446.3 million.